Biosimilar
Improving Accessibility & Affordability of Existing Biological Drugs
Prestige Biopharma aims to expand patient access to treatment by providing safe, quality and affordable biomedicines. Our biosimilar portfolio consists of 12 pipelines, including our HD201 (trastuzumab) in completion of Phase III, HD204 (bevacizumab) in Phase III and PBP1502 (adalimumab) in Phase I.
HD201
Trastuzumab Biosimilar
Breast Cancer, Gastric Cancer
Discovery
Preclinical
Phase I
Phase III
Filing
Approval
HD204
Bevacizumab Biosimilar
Solid Tumors
Discovery
Preclinical
Phase I
Phase III
Filing
Approval
PBP1502
Adalimumab Biosimilar
Arthritis
Discovery
Preclinical
Phase I
Phase III
Filing
Approval
PBP1601
Denosumab Biosimilar
Bone Loss, Osteoporosis
Discovery
Preclinical
Phase I
Phase III
Filing
Approval
PBP1602
Aflibercept Biosimilar
Macular Edema, Metastatic Colorectal Cancer, Retinopathy
Discovery
Preclinical
Phase I
Phase III
Filing
Approval
PBP1603
Eculizumab Biosimilar
Atypical Hemolytic Uremic Syndrome, Paroxysmal Nocturnal Hemoglobinuria
Discovery
Preclinical
Phase I
Phase III
Filing
Approval
PBP1701
Ipilimumab Biosimilar
Metastatic / Unresectable Melanoma
Discovery
Preclinical
Phase I
Phase III
Filing
Approval
PBP1801
Pertuzumab Biosimilar
Breast Cancer
Discovery
Preclinical
Phase I
Phase III
Filing
Approval
PBP2001
Ramucirumab Biosimilar
Metastatic / Gastric Junction Adenocarcinoma
Discovery
Preclinical
Phase I
Phase III
Filing
Approval
PBP2002
Natalizumab Biosimilar
Active Crohn’s Disease
Discovery
Preclinical
Phase I
Phase III
Filing
Approval
PBP2101
Nivolumab Biosimilar
Metastatic Urothelial Carcinoma
Discovery
Preclinical
Phase I
Phase III
Filing
Approval
PBP2102
Pembrolizumab Biosimilar
Metastatic / Unresectable Melanoma
Discovery
Preclinical
Phase I
Phase III
Filing
Approval